Table 2.
MAP vs. AP chemotherapy in the adult cohort.
| MAP | AP | OR/MD (95%CI) | p-Value | |
|---|---|---|---|---|
| Age | ||||
| Mean SD, years | 27.3 7.8 | 40.7 15.1 | 13.5 (6.2–20.8) | 0.0006 * |
| Median, years | 26 | 40 | ||
| Range, years | (18–48) | (21–71) | ||
| Sex | ||||
| Male, N (%) | 13/22 (59%) | 14/23 (60.9%) | 0.92 (0.30–2.85) | 0.903 † |
| Female, N (%) | 9/22 (41%) | 9/23 (39.1%) | ||
| Primary metastases | ||||
| Absent, N (%) | 15/22 (68.2%) | 18/23 (78.3%) | 0.59 (0.16–2.40) | 0.444 † |
| Detected, N (%) | 7/22 (31.8%) | 5/23 (21.7%) | ||
| Site | ||||
| Axial, N (%) | 5/22 (22.7%) | 8/23 (34.8%) | 1.81 (0.48–6.46) | 0.372 † |
| Extremities, N (%) | 17/22 (77.3%) | 15/23 (65.2%) | ||
| Tumor Necrosis | ||||
| Mean SD, % | 57.3 32.6 | 64.4 29.1 | 7.0 (30.5– -16.5) | 0.545 * |
| Median, % | 50 | 70 | ||
| Range, % | (10–100) | (10–98) | ||
| 90% Necrosis, N (%) | 6/17 (35.3%) | 3/13 (23.1%) | 1.18 (0.36–7.88) | 0.469 † |
| 90% Necrosis, N (%) | 11/17 (64.7%) | 10/13 (76.9%) | ||
| Surgery | ||||
| Extremities | ||||
| Limb-Sparing, N (%) | 15/17 (88.2%) | 14/15 (93.3%) | 0.53 (0.03–5.09) | 0.621 † |
| Amputation, N (%) | 2/17 (11.8%) | 1/15 (6.7%) | ||
| Axial | ||||
| Resection, N (%) | 5/5 (100%) | 8/8 (100%) | ||
| No, N (%) | 0/0 (0%) | 0/0 (0%) |
(*) t-test; (†) chi-square test; OR, Odds Ratio; MD, Mean Difference; 95%CI, 95% Confidence Interval; AP, Doxorubicin-Cisplatin; MAP, Methotrexate-Doxorubicin-Cisplatin; SD, standard deviation.